15 June 2021
Eligo presents preclinical data demonstrating for the first time that Gut Microbiome Modulation via delivery of CRISPR nuclease impacts disease progression
Eligo Bioscience SA, a Paris, France-based microbiome engineering company, today announced that the Company presented preclinical data on its lead drug candidate, EB003, for...